You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
By combining genome sequence data with phylogenetics and other clues, two teams looked at the SARS-CoV-2 introductions that sparked outbreaks in North America and Europe.
In PNAS this week: genetic diversity of SARS-CoV-2 indicates neutral evolution, portable RT-LAMP method to detect SARS-CoV-2, and more.
Researchers have been using Nextstrain, which includes data for thousands of SARS-CoV-2 genomes, to study how the virus accrues mutations over time.
The researchers applied their approach to study the heterogeneity of immune cells and adapted a visualization tool to analyze the data.
Bloomberg writes that Fred Hutchinson Cancer Research Center's Trevor Bedford and his colleagues continue to use viral genomics to track SARS-CoV-2.
The PAVmed subsidiary will have the option to license the biomarkers for a year after the completion of a Phase II study evaluating their accuracy.
In Genome Biology this week: analysis of gut microbiomes from the Hispanic Community Health Study/Study of Latinos, collection of patient-derived tumor cells from gynecological cancers, and more.
The single-cell genomics firm will collaborate with Fred Hutchinson Cancer Research Center on a targeted sequencing panel for MRD monitoring in AML.
The Seattle-based firm will use the funding to improve AI integration and further develop its Paris 3D tumor organoid diagnostic and drug discovery platform.
In Genome Research this week: PeCanPIE platform for finding, annotating, and ranking pathogenic variants; commensal Escherichia coli analysis; and more.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.